cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Iovance Biotherapeutics Inc
12 own
14 watching
Current Price
$7.98
$-0.15
(-1.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,259.57M
52-Week High
52-Week High
18.73
52-Week Low
52-Week Low
5.42
Average Volume
Average Volume
2.66M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,259.57M
icon52-Week High18.73
icon52-Week Low5.42
iconAverage Volume2.66M
iconDividend Yield--
iconP/E Ratio--
What does the Iovance Biotherapeutics Inc do?
Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; and PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is headquartered in New York, New York.
Read More
How much money does Iovance Biotherapeutics Inc make?
News & Events about Iovance Biotherapeutics Inc.
Ticker Report
10days ago
Iovance Biotherapeutics (NASDAQ:IOVA Get Rating) had its price target hoisted by analysts at Truist Financial from $16.00 to $17.00 in a report issued on Tuesday, The Fly reports. The firm currently has a buy rating on the biotechnology companys stock. Truist Financial&#...
Globe Newswire
13days ago
23 January 2023 Clinigen divests Proleukin to Iovance Biotherapeutics for 166.7 million The deal includes a 41.7 million milestone payment and double-digit Proleukin global sales royalties Clinigen Limited (Clinigen) (the Company), the global pharmaceutical services company, has entered into an ...
Globe Newswire
13days ago
Acquisition of Worldwide Rights to Proleukin Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in Anti-PD...
PR Newswire
2 months ago
Thinking about buying stock in Iovance Biotherapeutics, Bilibili, Dada Nexus, Xpeng, or GDS Holdings? Thinking about buying stock in Iovance Biotherapeutics, Bilibili, Dada Nexus, Xpeng, or GDS Holdings? PR Newswire NEW YORK, Dec. 5, 2022 NEW YORK, Dec. 5, 2022 /PRNewswire...
Market News Video
2 months ago
In trading on Friday, shares of Iovance Biotherapeutics Inc (IOVA) touched a new 52-week low of 5.42/share. Thats a 15.18 share price drop, or -73.69% decline from the 52-week high of 20.60 set back on 12/28/2021...
Frequently Asked Questions
Frequently Asked Questions
What is Iovance Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Iovance Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Iovance Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Iovance Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Iovance Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Iovance Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Iovance Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Iovance Biotherapeutics Inc?
plus_minus_icon
What percentage is Iovance Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Iovance Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$7.98
$-0.15
(-1.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00